November 20, 2024 Vitara Biomedical Raises $50 Million in Additional Financing and Names Kim Rodriguez as New Chief Executive Officer Read more
November 13, 2024 Microbiotica Announces First Patient Dosed in its Phase 1b Trial (COMPOSER-1) of MB310, a Precision Microbiome Medicine, in Ulcerative Colitis Patients Read more
November 1, 2024 Xintela’s main owner Flerie undertakes to exercise warrants TO3 of approximately SEK 28 million and provides a bridge loan of SEK 9 million Read more
October 23, 2024 Toleranzia receives approximately SEK 37 million through the warrants of series TO4 which were exercised to approximately 85 percent Read more
October 7, 2024 Microbiotica Announces First Patient Dosed in its International Phase 1b Trial, MELODY-1 of MB097 Precision Microbiome Co-Therapy in Advanced Melanoma Read more
October 2, 2024 Toleranzia submits a clinical trial application (CTA) for the drug candidate TOL2 for the treatment of myasthenia gravis Read more
October 2, 2024 NorthX Biologics strengthens leadership team with Magnus Gustafsson as Chief Commercial Officer Read more
October 1, 2024 Egetis Therapeutics has successfully carried out directed share issuances amounting to SEK 300 million Read more
September 26, 2024 Nanologica Receives Order for NLAB Saga® Worth approx. SEK 3,7 Million from Returning Customer in China Read more
September 20, 2024 Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission Read more
September 19, 2024 Egetis submits a patent application to the United States Patent and Trademark Office for “Processes of Preparation” of tiratricol Read more
September 17, 2024 AnaCardio successfully completes first part of AC01 HFrEF study and provides a clinical update Read more
September 11, 2024 Synerkine Pharma receives European Orphan Drug Designation for SK-01 to treat Complex Regional Pain Syndrome Read more
September 2, 2024 Xintela signs agreement with Region Östergötland for GMP process development of cell therapy for burn patients Read more
August 29, 2024 Nanologica resolves on a fully underwritten rights issue of units of approx. SEK 99.4 million, an over-allotment issue of up to SEK 20 million, and raises bridge loans of SEK 15 million Read more
August 28, 2024 Toleranzia har erhållit teckningsförbindelser avseende nyttjande av teckningsoptioner av serie TO4 motsvarande cirka 71,14 procent Read more
August 28, 2024 Egetis – New post-hoc analysis reports effects of tiratricol on patient-centered outcome measures in patients with MCT8 deficiency Read more
August 27, 2024 Amarna Therapeutics Receives Constructive Feedback from FDA INTERACT Meeting for AM510 Gene Therapy Development Targeting Type 1 Diabetes Read more
August 27, 2024 Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies Read more
August 21, 2024 Egetis – New data shows tiratricol (Emcitate®) treatment in patients with MCT8 deficiency is associated with survival benefits Read more
August 16, 2024 Egetis submits responses to the European Medicines Agency’s Day 120 List of Questions for the Marketing Authorisation Application for tiratricol (Emcitate®) Read more
August 9, 2024 Lipum has received a negative preliminary report regarding the audit of the Horizon 2020 project Read more
July 26, 2024 Xspray Pharma Shares New Information on Dasynoc, a Novel CML Treatment in Development Read more
July 23, 2024 Mendus announces collaboration with Institut Bergonié to study ilixadencel in soft tissue sarcomas Read more
July 17, 2024 Egetis Therapeutics AB (publ) – European Thyroid Association recommends tiratricol (Emcitate®) as long-term therapy for all patients with MCT8 deficiency in new guidelines Read more
July 15, 2024 Xspray Pharma’s XS003 Study shows Matching Bioavailability to Tasigna at more than a 50% Lower Dose Read more
June 26, 2024 Stockholm3 reduces prostate cancer treatment costs and enhances diagnostic precision Read more
June 20, 2024 Mendus AB (publ) – ALISON trial data presented at ESMO Gynaecological Cancers demonstrate tumor-directed immune responses in the majority of patients treated with vididencel Read more
June 20, 2024 Nanologica receives order for NLAB Saga valued to approximately SEK 2 Million Read more
June 20, 2024 Egetis announces topline results of the Phase 2 Triac Trial II with Emcitate® (tiratricol) for MCT8 deficiency Read more
June 18, 2024 Lipum reports further progress where the multiple dose part of the phase i clinical study is completed Read more
June 3, 2024 Egetis awarded Promising Innovative Medicine designation in the UK for Emcitate® (tiratricol) for treatment of MCT8 deficiency Read more
May 31, 2024 Toleranzia AB conducts successful safety study of TOL2 in blood samples from patients with myasthenia gravis Read more
May 24, 2024 Atrogi Announces Publication on Advancements in Combatting Obesity and Metabolic Complications Read more
May 20, 2024 InDex Pharmaceuticals has entered into a conditional agreement regarding a reverse merger with Flerie Read more
April 22, 2024 Xspray Pharma Announces Fourth Product Candidate, targeting USD 2.3 billion Market Read more
April 22, 2024 Stockholm3 study awarded best abstract in the prostate cancer biopsy indication session at the 2024 European Association of Urology meeting Read more
April 8, 2024 Geneos Therapeutics Announces Positive Phase 1/2 Data for GT-30 Trial of Personalized Therapeutic Cancer Vaccine Read more
April 4, 2024 AnaCardio selected as finalist at the J.P. Morgan Asset Management: Life Sciences Innovation Summit Read more
March 28, 2024 Flerie Invest AB erhåller FDI-godkännande för budpliktsbudet avseende Lipum AB (publ) Read more
March 27, 2024 Mendus announces ethics committee approval for the AMLM22-CADENCE trial with lead product vididencel in AML Read more
March 18, 2024 Toleranzia reports positive outcome from advisory meeting with the German Medicines Agency for the TOL2 development program Read more
March 15, 2024 Mendus’ major shareholders and members of the Board of Directors and Management declare their intention to exercise warrants of series TO3 Read more
March 15, 2024 Mendus AB (publ) – The exercise period for warrants of series TO3 commences today Read more
March 14, 2024 Symcel raises 86 MSEK to develop the world’s fastest detection system of live bacteria Read more
March 14, 2024 Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes Read more
March 6, 2024 Flerie Invest AB lämnar ett kontant budpliktsbud till aktieägarna och konvertibelinnehavaren i Lipum AB (publ) samt offentliggör erbjudandehandling Read more
March 1, 2024 Flerie Invest AB har ökat sitt innehav i Lipum AB (publ) varigenom gränsen för budplikt passerats Read more
March 1, 2024 Flerie Invest AB has increased its holding in Lipum AB (publ), whereby the limit for mandatory bidding has been exceeded Read more
February 12, 2024 Nanologica delivers NLAB SIV™ to a customer in Asia to a value of over MSEK 4 Read more
February 12, 2024 FDA Accepts Xpray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31st of July Read more
February 7, 2024 Prokarium Achieves Milestone with First Patient Dosing in PARADIGM-1 Non-Muscle Invasive Bladder Cancer Clinical Trial Read more
January 30, 2024 Lipum reports positive interim results from clinical phase 1 study showing that SOL-116 reduces plasma BSSL levels in healthy subjects Read more
January 25, 2024 Synerkine Pharma appoints industry veteran Anders Ekblom to its Board of Directors Read more
January 17, 2024 AnaCardio receives second tranche of SEK 50 million, completing the previously announced Series A round Read more
